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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: A limited number of studies have examined the vaccine-specific antibody status
of children with cancer. There are disagreements over the guidelines for postcancer immuni-
zation strategy.
Methods: Our studywas an observational, cross-sectional retrospective review of data collected
on children who were seen in the outpatient clinic at King Abdullah Medical City, Oncology Cen-
ter, Jeddah, the Kingdom of Saudi Arabia. Our aim was to evaluate the seropositive status to
vaccine-preventable diseases:measles,mumps, rubella, diphtheria, tetanus, polio, andHaemo-
philus influenzae type B (HIB) in childhood cancer survivors at our center in order to plan future
vaccination for these children and establish a simple revaccination schedule.
Results: Forty-seven patients (21 boys and 26 girls) were included in the study. Age at the time of
cancer diagnosis (mean standard deviation) was 5.68 3.79 years and age at test samplingwas
10.68 3.79 years. Acute leukemia was the most common cancer (49% of patients), followed by
lymphoma (28%), brain tumors (13%), and solid tumors (10%). Treatment intensities (according to
the Treatment Intensity Rating Scale, version 3.0; ITR-3) were 2, 3, and 4 for 26 patients (55%), 20
patients (43%), and one patient (2.1%), respectively. We found that 93% of our patients were
considered seronegative (unprotected) for at least one vaccine-preventable disease. The sero-
negative rates for measles, mumps, rubella, diphtheria, tetanus, polio, and HIB were 46.8%,
36.2%, 36.2%, 46.8%, 61.7%, 17.1%, and 42.6%, respectively. Criteria including age at diagnosis,
age at sampling, type ofmalignancy, and treatment intensity were not significantly different be-
tween seropositive and seronegative patients.
Conclusion: Seronegative rates for vaccine-preventable diseases were very high in childhood
cancer survivors, which represented a subpopulation of high-risk patientswho could benefit from
revaccination. We suggest a universal revaccination approach for all childhood cancer survivors,niversity Children Hospital, AL-Gomhoria Street, 35516, Al-Mansoura, Egypt.
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4.0/).1. Introduction
Malignancy in children and its treatment cause partial im-
mune deficiencies, leading to increases of morbidity and
mortality.1,2 Declining levels of granulocytes, lymphocytes,
and natural killer cells are associated with an increasing
risk of bacterial, fungal, and protozoan infections.3e5 Most
children with cancer are diagnosed before completing their
general vaccination programs and they also may undergo
chemotherapy of variable intensity. Some children may
become susceptible to infection as antibody levels ach-
ieved with vaccinations decline or disappear during the
course of their disease and/or chemotherapy treatment.
The clinical implications of losing protection against
vaccine-preventable diseases are serious. There is risk for
potentially life-threatening infections, and this immuno-
compromised group may serve as a reservoir for the spread
of pathogens. Unfortunately, compliance with revaccina-
tion of childhood cancer survivors is poor.6
The aim of this study was to evaluate the serological
status of childhood cancer survivors after the end of
chemotherapy treatment and to estimate seronegative
rates of vaccine-preventable diseases including measles,
mumps, rubella, diphtheria, tetanus, pertussis, poliomy-
elitis, and Haemophilus influenza B (HIB). We also aimed to
evaluate any risk factors associated with loss of protective
antibodies.2. Materials and methods2.1. Patient population
During the period between July 2014 and December 2015,
the data were reviewed for cancer survivors who were on
long-term follow-up at King Abdullah Medical City Oncology
Center, Jeddah. Clinical data of each patient were
reviewed from patient medical records. Data for the vac-
cinations received were obtained from parents or the pa-
tient’s immunization card. The study was approved by the
Institutional Review Board of King Abdullah Medical City.2.2. Inclusion criteria
The study included children aged 1e18 years who had
completed their cancer treatment at least 3 months prior
to data collection, were in remission, and who had their
antibody levels checked for measles, mumps, rubella,
diphtheria, tetanus, polio, and HIB vaccines. Blood samples
were taken during routine follow-up blood work. Only pa-
tients with complete data were included.ayea NY, et al., Immunization Sta
gy (2016), http://dx.doi.org/10.12.3. Exclusion criteria
Children who received immunization postcancer treatment
or who were on active treatment for cancer and/or who
received blood or blood products including intravenous
immunoglobulin in the preceding 3e6 months. Other
exclusion criteria included previously diagnosed immuno-
deficiency or low immunoglobulin-G (IgG) levels in relation
to age.
Age at the time of sample collection and the time since
treatment completion were recorded.
2.4. Antibody assay
Different methods were used according to vaccine-specific
antibodies as follows: measles, mumps, and rubella anti-
bodies IgG by multiplex Flow Immunoassay (Rochester Lab,
NY, USA); diphtheria toxoid IgG and tetanus toxoid IgG an-
tibodies by the Enzyme Immune Assay (Rochester Lab,
Rochester, NY, USA); poliovirus 1, 2, 3 neutralizing anti-
bodies by enzyme-linked immunosorbent assay (Focus Di-
agnostics, Inc, CA, USA); and HIB antibodies (IgG) by
enzyme-linked immunosorbent assay (Rochester Lab,
Rochester, NY, USA).7
The results were either seropositive or seronegative
based on the laboratory test manufacturer’s guidelines.
Patients who had the following levels were considered to
have a protective titer for specific related infection (sero-
positive/protected): measles IgG > 13.5 AU/mL, mumps >
9 AU/mL, rubella > 10.0 IU/mL, diphtheria toxoid IgG an-
tibodies > 0.01 IU/mL, tetanus toxoid IgG antibodies >
0.01 IU/mL, polio neutralizing antibody titer 1:8 up to >
1:28, and HIB IgG antibodies  1.0 mg/L.
For analysis purposes, patients were divided into two
groups: “seropositive” or “protected” patients with anti-
body titers equal to or above previously cutoff levels, and
“seronegative” or “unprotected” for those with antibody
titers below the previously mentioned cutoff levels.
Treatment intensity was determined for each patient
using a published scale using the Intensity of Treatment
Rating Scale, version 3.0 (ITR-3). ITR-3 is a scale which
classifies treatments into four defined levels of intensity
based on diagnosis, stage, and treatment data (surgery,
chemotherapy, radiation, and transplant) from medical
records (Level 1 indicates least intensive treatments, Level
2 moderately intensive treatments, Level 3 very intensive
treatments, and Level 4 most intensive treatments).8
2.5. Statistical analysis
Data analysis was mainly descriptive. Numeric data were
presented as mean standard deviation (SD), or as mediantus in Childhood Cancer Survivors: A Hidden Risk Which Could be
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cording to the type of distribution of each variable. Fre-
quency and percentages for categorical variables were
used. The Chi-square test was used to compare between
different variables. A p value < 0.05 was considered sta-
tistically significant.
3. Results
Forty-seven patients (21 boys [44.7%] and 26 girls [55.3%])
were included. The age at the time of cancer diagnosis
(mean SD) was 5.67 3.60 years, and the median was
4.39 years (IQR: 2.74e8.93 years). Patients’ characteristics
are summarized in Table 1.
Age at the time of sample collection (mean SD) was
10.27 3.40 years, and the median was 12.55 (IQR:
7.84e10.06) years. Time from end of treatment to sampling
(mean SD) was 3.02 2.64 years, and the median was
1.90 (IQR: 0.74e5.09 years; minimum: 0.64 years,
maximum: 8.59 years).
All patients had a normal level of IgG in relation to age.
Total IgG level (mean SD)was 1242.97 276.01mg/dL, and
themedianwas1250.00mg/dL (IQR1060.00e1455.00mg/dL;
minimum: 687.0 mg/dL, maximum: 1840.00 mg/dL).
Regarding vaccines received prior to the start of cancer
treatment, 20 patients (42.6%) were fully vaccinated
(received all compulsory vaccines), whereas 23 patientsTable 1 Characteristics of the children included in the
study.
Variable No. (%)
Sex
Male 21 (44.7)
Female 26 (55.3)
Age at diagnosis (y)
Mean SD 5.67 3.60
Median (IQR) 4.39 (2.74e8.93)
Age at sample collection (y)
Mean SD 10.27 3.40
Median y (IQR) 12.55 (7.84e10.06)
Duration from end of treatment to testing (y)
Mean SD 3.02 2.64
Median y (IQR) 1.90 (0.74e5.09)
(minimum to maximum) (0.64e8.59)
Treatment intensity received
I 0
II 26 (55.3)
III 20 (42.6)
IV 1 (2.1)
Malignancy types
Leukemia 23 (48.9)
Lymphoma 13 (27.7)
Solid tumor 5 (10.6)
Brain tumor 6 (12.8)
Vaccinations received prior to treatment
Fully 20 (42.6)
Incompletely vaccinated 23 (49.4)
No vaccine 4 (8.5)
IQRZ inter quartile range; SDZ standard deviation.
Please cite this article in press as: Fayea NY, et al., Immunization Sta
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tients (8.5%) had not received any vaccine according to the
National Saudi Vaccination Program.
Treatment intensities as per the ITR-3 were 2, 3, and 4 of
26 patients (55%), 20 patients (43%), and one patient
(2.1%), respectively.
Acute leukemia was the most common cancer in 23 pa-
tients (48.9%), followed by lymphoma in 13 patients
(27.7%). Brain tumor was diagnosed in six patients (12.8%)
and solid tumor in only five patients (10.6%). Different se-
ropositivities for different vaccines in different types of
cancer are shown in Table 2.
Our analysis revealed that 93% of our patients were
considered to be seronegative for at least one vaccine-
preventable disease. The seronegative rates for measles,
mumps, and rubella were 46.8%, 36.2%, and 36.2%,
respectively. Seronegative rates for diphtheria, tetanus,
polio, and HIB were 46.8%, 61.7%, 17.1%, and 42.6%,
respectively. Different criteria including age of diagnosis,
age of sampling, type of malignancy, treatment intensity,
and time of sample collection from end of treatment were
not significantly different between seropositive and sero-
negative patients (Table 3).4. Discussion
The percentage of childhood cancer survivors whose anti-
bodies fall below the protective level differs widely. There
is no clear clue to determine who is going to lose antibodies
against which common vaccine antigens.
In our study, w93% of patients were considered sero-
negative (unprotected) for at least one vaccine-
preventable disease.
Age of the patients on diagnosis or age on sampling did
not significantly differ between seropositive and seroneg-
ative patients. Similar findings have been reported previ-
ously,9 but other studies reported that the younger the
patient age upon cancer diagnosis the more rapid the
decrease in protective antibody levels.10e13
We found that different types of cancer had no signifi-
cant influence on antibody levels to different vaccines.
Similar findings have been reported in a number of
studies.2,11,12,14 However, one study demonstrated that
protection rates depended on the underlying malignancy
and chemotherapeutic regimen.15
In our study, treatment intensity did not show a signifi-
cant difference on antibody levels, which was similar to
that reported by Patel at al.9 However, other studies found
that the intensity of acute lymphoblastic leukemia treat-
ment could influence immune responses.16e18
In our study, the seronegative rates for measles, mumps,
and rubella were 46.8%, 36.2%, and 36.2%, respectively.
Seronegative rates for diphtheria, tetanus, polio, and HIB
were 46.8%, 61.7%, 17.1%, and 42.6%, respectively. Signifi-
cant post-treatment decreases in measles and mumps,
diphtheria, and tetanus antibodies were observed in 43%,
31%, 52%, and 44% of the children, respectively.13 Zignol
et al12 suggested that chemotherapy might induce a loss of
protective serum antibody titers for rubella, mumps, and
measles in 18%, 21%, and 25% of patients, respectively.
Bochennek et al19 reported loss of humoral immunitytus in Childhood Cancer Survivors: A Hidden Risk Which Could be
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Table 3 Seropositive rates of different vaccines grouped according to age on diagnosis and treatment intensity.
Vaccine Serologic results Age at diagnosis (y) Age at testing (y) Treatment intensity
Seropositive
(protected)
n (%)
Seronegative
(unprotected)
n (%)
< 7
NZ 32
n (%)
> 7
NZ 15
n (%)
p* < 10
NZ 23
n (%)
> 10
NZ 24
n (%)
p* II
NZ 26
n (%)
III
NZ 20
n (%)
IV
NZ 1
n (%)
p*
Measles 25 (53.2) 22 (46.8) 17 (53.1) 8 (53.3) 0.85 13 (56.5) 12 (50.0) 0.81 16 (61.5) 9 (45.0) 0 0.15
Mumps 30 (63.8) 17 (36.2) 19 (59.4) 11 (73.3) 0.45 12 (52.2) 18 (75.0) 0.34 16 (61.5) 14 (70.0) 0 0.65
Rubella 30 (63.8) 17 (36.2) 21 (65.6) 9 (60.0) 0.40 15 (65.2) 15 (62.5) 1.00 18 (69.2) 12 (60.0) 0 0.54
Diphtheria 25 (53.2) 22 (46.8) 16 (50) 9 (60.0) 0.79 12 (52.2) 13 (54.2) 0.81 14 (53.8) 10 (50.0) 1 (100) 0.80
Tetanus 18 (38.3) 29 (61.7) 11 (34.4) 7 (46.7) 0.42 7 (30.4) 11 (45.8) 0.53 10 (38.5) 8 (40.0) 0 0.90
Polio 39 (82.9) 8 (17.1) 28 (87.5) 11 (73.3) 0.48 20 (86.9 19 (79.2) 0.81 23 (88.5) 15 (75.0) 1 (100) 0.70
HIB 27 (57.4) 20 (42.6) 17 (53.1) 10 (66.7) 0.75 13 (56.5) 14 (58.3) 0.81 14 (53.8) 12 (60.0) 1 (100) 0.86
* A p value < 0.05 was taken to be significant.
HIBZHaemophilus influenzae type B.
Table 2 Seropositive rates to different vaccines grouped according to underlying type of malignancy.
Vaccine Leukemia
NZ 23
n (%)
Lymphoma
NZ 13
n (%)
Solid tumors
NZ 5
n (%)
Brain tumor
NZ 6
n (%)
p*
Measles 11 (47.8) 9 (69.2) 2 (40.0) 3 (50.0) 0.836
Mumps 13 (56.5) 9 (69.2) 5 (100.0) 3 (50.0) 0.444
Rubella 12 (52.2) 10 (76.9) 4 (80.0) 2 (33.3) 0.575
Diphtheria 9 (39.1) 10 (76.9) 3 (60.0) 3 (50.0) 0.375
Tetanus 7 (30.4) 8 (61.5) 1 (20.0) 2 (33.3) 0.438
Polio 20 (87.0) 12 (92.3) 4 (80.0) 3 (50.0) 0.199
Haemophilus 12 (52.2) 8 (61.5) 3 (60.0) 4 (66.7) 0.857
* A p value < 0.05 was taken to be significant.
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of patients, respectively. However, Nilsson et al11 reported
persistence of protective levels of antibodies in a high
percentage of children after chemotherapy against measles
(in 60%) and rubella (in 72%). Patel et al9 also reported that
the majority of children in their study had levels of pro-
tective antibodies for tetanus (100%), HIB (87%), and mea-
sles (71%) antigens.
In our study, loss of protective antibodies against polio
was detected in 17.1% of patients. Zingol et al12 reported
losses of protective serum antibody titers in only 8% of
patients. Another study reported a higher percentage of
decrease of polio antibodies below the protective level in
12e25% of the children studied.13 However, Patel et al9
found only 11% of patients with acute leukemia had pro-
tective titers to all poliovirus serotypes after the end of the
treatment.
Differences between studies may be due to variations in
the types of vaccines used, populations, or treatment pro-
tocols. Also, different antibody tests and protective cutoff
levels might also be responsible. Although the reason for the
loss of protective vaccination antibodies in blood is not fully
understood, the loss of humoral immunity has been
demonstrated and linked to chemotherapy-induced alter-
ations of the immune system.20e23 Our practice during the
study was to revaccinate all childhood cancer survivors ac-
cording to specific antibodies results of each patient. For
those who had an unprotective antibody titer, wePlease cite this article in press as: Fayea NY, et al., Immunization Sta
Prevented, Pediatrics and Neonatology (2016), http://dx.doi.org/10.1recommended revaccination at the nearby primary health
facility. Guidelines for child revaccination after end of
chemotherapy are few. The United States guidelines (Cen-
ters for Disease Control and Prevention, 1993)24 recommend
revaccination 3 months after completion of chemotherapy.
The current UK guidelines (Royal College of Paediatrics and
Child Health, 2002)25 recommend revaccination at 6 months
after completion of standard chemotherapy. However, there
is still debate with regards to the cost of universal revacci-
nation after the end of cancer treatment, compared with
the cost of laboratory antibody testing and then selective
specific revaccination (which may be more costly and time-
consuming). Also, there are still no clear cutoff levels for
protective antibody titers to be used for revaccination in
childhood cancer survivors. We agree with the previous
opinion that universal revaccination is likely to be the most
easily applicable, low-cost approach and therefore the most
useful in developing countries.9
4.1. Limitations of the study
We did not measure vaccine antibodies at time of cancer
diagnosis or after revaccination due to the high cost of
antibody testing and limited resources. Also, there was no
control group due to difficulties in recruitment and debate
regarding the use of different levels of vaccines in healthy
children’s antibodies to be compared with those levels of
cancer survivors.tus in Childhood Cancer Survivors: A Hidden Risk Which Could be
016/j.pedneo.2016.04.003
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+ MODEL5. Conclusion
Seronegative rates for vaccine-preventable diseases were
very high in childhood cancer survivors, which represented
a subpopulation of high-risk patients who could benefit
from revaccination. We suggest a universal revaccination
approach for all childhood cancer survivors, which is easily
applicable and of low cost.
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